Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Chao Wang, Yujing Zhang, Tingting Zhang, Lingyu Shi, Zhongmin Geng & Dongming Xing. (2022) Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 1667-1693.
Read now
Read now
Andrew B. Benowitz, Katherine L. Jones & John D. Harling. (2021) The therapeutic potential of PROTACs. Expert Opinion on Therapeutic Patents 31:1, pages 1-24.
Read now
Read now
Michael D. Wiese, Arkady T. Manning-Bennett & Ahmad Y. Abuhelwa. (2020) Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs 29:5, pages 475-482.
Read now
Read now
Articles from other publishers (35)
Shanshan Wei, Ting Liu, Yani Zhao, Yang Xiao, Dongsheng Zhou, Jinxian Zheng, Dong Zhou, Zhili Ding, Qiyou Xu, Samwel Mchele Limbu & Youqin Kong. (2023)
Combined effects of dietary carbohydrate levels and ammonia stress on growth, antioxidant capacity and glucose metabolism in juvenile oriental river prawn (
Macrobrachium nipponense
)
. Journal of Experimental Zoology Part A: Ecological and Integrative Physiology 339:10, pages 978-993.
Crossref
Crossref
Fleur M. Ferguson. (2023) PROTACs reach clinical development in inflammatory skin disease. Nature Medicine.
Crossref
Crossref
Yun Chen, Yi Ning, Zhiwei Chen, Yaping Xue, Qingyun Wu, Wenhu Duan, Jian Ding, Jinpei Zhou, Hua Xie & Huibin Zhang. (2023) Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry 256, pages 115453.
Crossref
Crossref
Vijayakumar Gosu, Santanu Sasidharan, Prakash Saudagar, Kamalakannan Radhakrishnan, Hak-Kyo Lee & Donghyun Shin. (2023) Deciphering the intrinsic dynamics of unphosphorylated IRAK4 kinase bound to type I and type II inhibitors. Computers in Biology and Medicine 160, pages 106978.
Crossref
Crossref
Hiroshi Inami, Tsuyoshi Mizutani, Junko Watanabe, Hisashi Hayashida, Tomonori Ito, Takeshi Terasawa, Toru Kontani, Hiroaki Yamagishi, Hiroyuki Usuda, Naohiro Aoyama, Emiko Imamura & Takeshi Ishikawa. (2023) Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction. Bioorganic & Medicinal Chemistry 87, pages 117302.
Crossref
Crossref
Yongjin Hao, Jin Wang, Jiawan Ma, Xiaoliang Yu, Zhanhui Li, Shuwei Wu, Sheng Tian, Haikuo Ma, Sudan He & Xiaohu Zhang. (2023) Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model. Bioorganic Chemistry, pages 106584.
Crossref
Crossref
Saynaz A. Choudhary, Debarun Patra, Archana Sinha, Sayani Mazumder, Rajat Pant, Raju Chouhan, Anupam Nath Jha, Biswa Mohan Prusty, Debasis Manna, Sajal K. Das, Kulbhushan Tikoo, Durba Pal & Suman Dasgupta. (2023) A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo. European Journal of Pharmacology 944, pages 175593.
Crossref
Crossref
César A. Zapata‐Acevedo, José Manuel Guevara‐Vela, Paul L. A. Popelier & Tomás Rocha‐Rinza. (2022) Binding Energy Partition of Promising IRAK‐4 Inhibitor (Zimlovisertib) for the Treatment of COVID‐19 Pneumonia. ChemPhysChem 23:24.
Crossref
Crossref
Swapnil P. Bhujbal, Weijie He & Jung-Mi Hah. (2022) Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies. Molecules 27:19, pages 6307.
Crossref
Crossref
Tingting Yao, Heng Xiao, Hong Wang & Xiaowei Xu. (2022) Recent Advances in PROTACs for Drug Targeted Protein Research. International Journal of Molecular Sciences 23:18, pages 10328.
Crossref
Crossref
Qianqian Li, Rui Li, Hanlin Yin, Suli Wang, Bei Liu, Jun Li, Mi Zhou, Qingran Yan & Liangjing Lu. (2022) Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomedicine & Pharmacotherapy 153, pages 113459.
Crossref
Crossref
Iain A. Cumming, Sébastien L. Degorce, Anna Aagaard, Erin L. Braybrooke, Nichola L. Davies, Coura R. Diène, Andrew J. Eatherton, Hannah R. Felstead, Sam D. Groombridge, Eva M. Lenz, Yunxia Li, Youfeng Nai, Stuart Pearson, Graeme R. Robb, James S. Scott, Oliver R. Steward, Chengyan Wu, Yafeng Xue, Lanping Zhang & Yanxiu Zhang. (2022) Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors. Bioorganic & Medicinal Chemistry 63, pages 116729.
Crossref
Crossref
Alexander Spasov, Vadim Kosolapov, Denis Babkov, Vladlen Klochkov, Elena Sokolova, Mikhail Miroshnikov, Alexander Borisov, Yulia Velikorodnaya, Alexey Smirnov, Konstantin Savateev, Victor Fedotov, Svetlana Kotovskaya & Vladimir Rusinov. (2022) Discovery of Nitro-azolo[1,5-a]pyrimidines with Anti-Inflammatory and Protective Activity against LPS-Induced Acute Lung Injury. Pharmaceuticals 15:5, pages 537.
Crossref
Crossref
Sairah Ahmed, Qiuhong Zhao, Walter Hanel, Muzaffar H. Qazilbash, Krina Patel, Ravi Narra, Ankit Kansagra, Madiha Iqbal, Farrukh T. Awan, Beth Christian, Samantha M. Jaglowski, Mohamed A. Kharfan‐Dabaja, Mehdi Hamadani & Narendranath Epperla. (2021) Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological Oncology 40:1, pages 49-57.
Crossref
Crossref
Sarbjit Singh, Divya Utreja & Vimal Kumar. (2021) Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy. Medicinal Chemistry Research 31:1, pages 1-25.
Crossref
Crossref
Dirk Föll & Tilmann Kallinich. 2022. Pädiatrische Rheumatologie. Pädiatrische Rheumatologie
291
309
.
Chao Wang, Yujing Zhang, Dongming Xing & Renshuai Zhang. (2021) PROTACs technology for targeting non-oncoproteins: Advances and perspectives. Bioorganic Chemistry 114, pages 105109.
Crossref
Crossref
Jiamin Zheng, Jun Wu, Xiao Ding, Hong C. Shen & Ge Zou. (2021) Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 38, pages 127862.
Crossref
Crossref
Jiaqi Xu, Qiuhui Qian, Min Xia, Xuedong Wang & Huili Wang. (2021) Trichlorocarban induces developmental and immune toxicity to zebrafish (Danio rerio) by targeting TLR4/MyD88/NF-κB signaling pathway. Environmental Pollution 273, pages 116479.
Crossref
Crossref
Wenqiang Zhai, Yongping Lu, Yabo Zhu, Mengguang Zhou, Cheng Ye, Zheng-Zheng Shi, Wenjian Qian, Taishan Hu & Lei Chen. (2021) Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors. Bioorganic & Medicinal Chemistry Letters 31, pages 127686.
Crossref
Crossref
Dirk Föll & Tilmann Kallinich. 2020. Pädiatrische Rheumatologie. Pädiatrische Rheumatologie
1
19
.
Jiang Liu, Jianlin Han, Kunisuke Izawa, Tatsunori Sato, Sarah White, Nicholas A. Meanwell & Vadim A. Soloshonok. (2020) Cyclic tailor-made amino acids in the design of modern pharmaceuticals. European Journal of Medicinal Chemistry 208, pages 112736.
Crossref
Crossref
Jing Zhang, Liqiang Fu, Bin Shen, Yingtao Liu, Wenqian Wang, Xin Cai, Linglong Kong, Yilin Yan, Ryan Meng, Zhuming Zhang, Ying-Nan P. Chen, Qian Liu, Zhao-Kui Wan, Tianyuan Zhou, Xiaotao Wang, Paul Gavine, Amanda Del Rosario, Kay Ahn, Ulrike Philippar, Ricardo Attar, Jennifer Yang, Yanping Xu, James P. Edwards & Xuedong Dai. (2020) Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. Cell Chemical Biology 27:12, pages 1500-1509.e13.
Crossref
Crossref
Lingfeng Chen, Lulu Zheng, Pengqin Chen & Guang Liang. (2020) Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling. Journal of Medicinal Chemistry 63:22, pages 13316-13329.
Crossref
Crossref
Gloria Pastor-Fernández, Isabel R. Mariblanca & María N. Navarro. (2020) Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities. Cells 9:9, pages 2044.
Crossref
Crossref
Satheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, Ramesh Sistla, Durgarao Kantheti, Subba Rao Polimera, Soodamani Thangavel, Amrita Jha Mukherjee, Mitalee Das, Rajeev S. Bhide, William J. Pitts, Natesan Murugesan, Shailesh Dudhgoankar, Jignesh Nagar, Siva Subramani, Debarati Mazumder, Julie A. Carman, Deborah A. Holloway, Xin Li, Mark P. Fereshteh, Stefan Ruepp, Kamalavenkatesh Palanisamy, T. Thanga Mariappan, Srinivas Maddi, Ajay Saxena, Paul Elzinga, Anjaneya Chimalakonda, Qian Ruan, Kaushik Ghosh, Sucharita Bose, John Sack, Chunhong Yan, Susan E. Kiefer, Dianlin Xie, John A. Newitt, S. Pon Saravanakumar, Richard A. Rampulla, Joel C. Barrish, Percy H. Carter & John HynesJr.Jr.. (2020) Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis. ACS Medicinal Chemistry Letters 11:7, pages 1402-1409.
Crossref
Crossref
Theodore MellorsJohanna B. WithersAsher AmeliAlex JonesMengran WangLixia ZhangHelia N. SanchezMarc SantoliniItalo Do ValleMichael SebekFeixiong ChengDimitrios A. PappasJoel M. Kremer, Jeffery R. CurtisKeith J. JohnsonAlif SalehSusan D. GhiassianViatcheslav R. Akmaev. (2020) Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. Network and Systems Medicine 3:1, pages 91-104.
Crossref
Crossref
Luana Chiquetto Paracatu & Laura G. Schuettpelz. (2020) Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes. Frontiers in Immunology 11.
Crossref
Crossref
Cesar A. Corzo, Eugene Varfolomeev, A. Francesca SetiadiRoss Francis, Sha KlabundeKate Senger, Swathi Sujatha-BhaskarJoy DrobnickSteven DoEric Suto, Zhiyu HuangJeffrey Eastham-AndersonArna KatewaJodie Pang, Melanie DomeyerChristopher Dela Cruz, Andres Paler-Martinez, Vivian W. C. Lau, Azadeh HadadianpourVladimir Ramirez-Carrozi, Yonglian Sun, Katherine Bao, Daqi XuEmily HunleyHans D. Brightbill, Soren Warming, Merone Roose-Girma, Alfred Wong, Lucinda Tam, Claire L. EmsonJames J. Crawford, Wendy B. YoungRajita PappuBrent S. McKenzie, Vida AsghariDomagoj Vucic, Jason A. Hackney, Cary D. Austin, Wyne P. Lee, Annemarie Lekkerkerker, Nico Ghilardi, Marian C. Bryan, James R. Kiefer, Michael J. TownsendAli A. Zarrin. (2020) The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. Science Signaling 13:634.
Crossref
Crossref
Angélica Vega-García, Luisa Rocha, Rosalinda Guevara-Guzmán, Christian Guerra-Araiza, Iris Feria-Romero, Juan M. Gallardo, Teresa Neri-Gomez, José E. Suárez-Santiago & Sandra Orozco-Suarez. (2020) Magnolia officinalis Reduces Inflammation and Damage Induced by Recurrent Status Epilepticus in Immature Rats. Current Pharmaceutical Design 26:12, pages 1388-1401.
Crossref
Crossref
Naomi S. Rajapaksa, Alberto Gobbi, Joy Drobnick, Steven Do, Aleksandr Kolesnikov, Jun Liang, Yongsheng Chen, Swathi Sujatha-Bhaskar, Zhiyu Huang, Hans Brightbill, Ross Francis, Christine Yu, Edna F. Choo, Kevin DeMent, Yingqing Ran, Le An, Claire Emson, Jonathan Maher, John Wai, Brent S. McKenzie, Patrick J. Lupardus, Ali A. Zarrin, James R. Kiefer & Marian C. Bryan. (2019) Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity. ACS Medicinal Chemistry Letters 11:3, pages 327-333.
Crossref
Crossref
Yun Chen, Gang Bai, Yi Ning, Shi Cai, Tao Zhang, Peiran Song, Jinpei Zhou, Wenhu Duan, Jian Ding, Hua Xie & Huibin Zhang. (2020) Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry 190, pages 112092.
Crossref
Crossref
Julien Blaess, Julia Walther, Arthur Petitdemange, Jacques-Eric Gottenberg, Jean Sibilia, Laurent Arnaud & Renaud Felten. (2020) Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2095997.
Crossref
Crossref
Sébastien L. Degorce, Rana Anjum, Andrew Bloecher, Rodrigo J. CarbajoKeith S. Dillman, Lisa Drew, Christopher T. HalsallEva M. LenzNicola A. LindsayMichele F. Mayo, Jennifer H. PinkGraeme R. Robb, Alan Rosen, James S. Scott & Yafeng Xue. (2019)
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
L265P
Mutant Diffuse Large B Cell Lymphoma
. Journal of Medicinal Chemistry 62:21, pages 9918-9930.
Crossref
Crossref
Teja Celhar, Hao Kim Lu, Lia Benso, Larissa Rakhilina, Hui Yin Lee, Shubhita Tripathi, Olga Zharkova, Wei Yee Ong, Hiroko Yasuga, Bijin Au, Damien Marlier, Lina Hsiu Kim Lim, Thomas Paulraj Thamboo, John S. Mudgett, Matthew F. Mackey, Dennis M. Zaller, John E. Connolly & Anna-Marie Fairhurst. (2019) TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, and IRAK4 Dependent Manner. Frontiers in Immunology 10.
Crossref
Crossref